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Abstract
Background: Vascular remodeling in response to alterations in blood flow has been shown to modulate the formation of
neo-intima. This process results from a proliferative response of vascular smooth muscle cells and is influenced by
macrophages, which potentiate the development of the intima. The LDL receptor-related protein 1 (LRP1) is a large
endocytic and signaling receptor that recognizes a number of ligands including apoE-containing lipoproteins, proteases
and protease-inhibitor complexes. Macrophage LRP1 is known to influence the development of atherosclerosis, but its role
in vascular remodeling has not been investigated.
Methodology/Principal Findings: To define the contribution of macrophage LRP1 to vascular remodeling, we generated
macrophage specific LRP1-deficient mice (macLRP1-/-) on an LDL receptor (LDLr) knock-out background. Using a carotid
ligation model, we detected a 2-fold increase in neointimal thickening and a 2-fold increase in the intima/media ratio in
macLRP1-/- mice. Quantitative RT-PCR arrays of the remodeled vessel wall identified increases in mRNA levels of the TGF-b2
gene as well as the Pdgfa gene in macLRP1-/- mice which could account for the alterations in vascular remodeling.
Immunohistochemistry analysis revealed increased activation of the TGF-b signaling pathway in macLRP1-/- mice. Further,
we observed that LRP1 binds TGF-b2 and macrophages lacking LRP1 accumulate twice as much TGF-b2 in conditioned
media. Finally, TNF-a modulation of the TGF-b2 gene in macrophages is attenuated when LRP1 is expressed. Together, the
data reveal that LRP1 modulates both the expression and protein levels of TGF-b2 in macrophages.
Conclusions/Significance: Our data demonstrate that macrophage LRP1 protects the vasculature by limiting remodeling
events associated with flow. This appears to occur by the ability of macrophage LRP1 to reduce TGF-b2 protein levels and to
attenuate expression of the TGF-b2 gene resulting in suppression of the TGF-b signaling pathway.
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Introduction
The LDL receptor-related protein 1 (LRP1) is a large endocytic
receptor that was initially identified as an hepatic receptor for a2-
macroglobulin complexes [1–3]. Subsequent work has revealed that
LRP1 recognizes numerous ligands and contributes to a variety of
cellular functions and signaling events [4,5]. Within the vasculature,
LRP1 appears to play a protective role. Thus, generation of an
LRP1 knock-in mouse with mutations in a critical NPxYxxL motif
within its cytoplasmic domain resulted in increased atherosclerosis
when crossed into an LDLr-deficient background [6], revealing
that impaired function of LRP1 alters the progression of this
disease. Further, hepatic deletion of LRP1 also led to increased
atherosclerosis indicating that hepatic LRP1 function also regulates
the development of atherosclerosis. Mice with LRP1 genetically
deleted in vascular smooth muscle cells display excessive activation
of the PDGF signaling pathway resulting from increased expression
of the PDGFR in the vessel wall [7] demonstrating that in smooth
muscle cells, LRP1 protects the vasculature by suppressing the
excessive activity of this pathway. Deletion of LRP1 within
macrophages has been shown to enhance the extent of atheroscle-
rosis in LDL receptor/apoE double knockout mice [8] and in LDL
receptor knockout mice receiving a bone marrow transplant from
mice in which LRP1 was selectively deleted in macrophages [9].
Currently, the mechanism by which macrophage LRP1 impairs
lesion development in atherosclerosis is not understood.
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atherosclerosis, macrophages are also known to contribute to
restenosis. Restenosis and in-stent restenosis occurs following
percutaneous balloon angioplasty, an established method for
treating severe coronary artery blockage [10]. Restenosis involves
significant vascular remodeling including excessive deposition
of matrix proteins, as well as migration and proliferation of
vascular smooth muscle cells. In response to injury, these cells de-
differentiate from a quiescent, differentiated state to a proliferating
and synthetic phenotype [11]. Major contributors to these
processes are the PDGF [12] and TGF-b [13] signaling pathways.
To determine if macrophage LRP1 modulates vascular remodel-
ing during restenosis and to gain mechanistic insight into these
processes, we initiated studies comparing macrophage-deleted
LRP1 mice (macLRP1-/-) to control mice expressing LRP1 in an
established model of carotid artery ligation [14]. Our results reveal
that macrophage LRP1 suppresses neointima formation, and
further implicate a mechanism in which LRP1 modulates the
TGF-b signaling pathway.
Results
Genetic deletion of LRP1 in macrophages increases
intimal hyperplasia following carotid artery ligation
To evaluate the contribution of macrophage LRP1 to vascular
remodeling, we employed the well characterized carotid artery
ligation model [14]. The contribution of macrophages to arterial
wall remodeling is well established [15,16] and occurs early in this
model. Further, macrophage contribution is significantly enhanced
in apoE- or LDL receptor (LDLr)-deficient mice maintained on a
high fat diet [15], and thus we generated a macrophage specific
LRP1 knock-out mouse on an LDLr-/- background (termed,
macLRP1-/-) and evaluated vascular remodeling when the mice
were maintained on a high fat, Western-type diet. To evaluate the
effectiveness of the genetic deletion, bone marrow derived
macrophages from LRP1+/+ and macLRP1-/- mice were
subjected to immunoblot analysis. The results (Fig. 1a) reveal
effective deletion of LRP1 in macrophages from the macLRP1-/-
mice consistent with our previous results [17]. LRP1 function was
also ablated in resident macrophages obtained by peritoneal lavage.
Thiswasconfirmedbymeasuring the abilityofcellsstainingpositive
for the macrophage marker F4/80 from macLRP1-/- mice to
internalize fluorescent-labeled receptor associated protein (RAP)
which binds tightly to LRP1 (Fig. 1b). Together, these results reveal
an effective ablation of LRP1 antigen in bone-marrow derived and
resident macrophages in the macLRP1-/- mice.
No morphological differences were noted in the carotid arteries
of untreated mice when macLRP1-/- mice were compared with
control mice (LRP1+/+, also on an LDLr-/- background). In
contrast, two weeks following ligation with the mice maintained on
a Western diet, we detected much more extensive remodeling in
the macLRP1-/- mice than noted in LRP1+/+ sibling mice
(Fig. 2). We stained consecutive sections with elastic-Van Gieson
(EVG) (Fig. 2a) to detect the elastic lamina and H&E (Fig. 2b) to
detect the cellular composition of the neointima. These data
revealed that carotid arteries from both LRP1+/+ and
macLRP1-/- mice have a highly cellular neointima (Fig. 2b).
Remodeling was measured by morphometric analyses of the
intimal area and by calculating the ratio of intimal area to medial
area which were determined on EVG stained paraffin sections.
These analyses revealed a 2.4-fold increase in neointimal
thickening and in the intima/media ratio in macLRP1-/- vessels
compared to vessels from LRP1+/+ mice (Fig. 2c,d). In addition,
the overall area of the vessels was slightly larger in the
macLRP1-/- mice.
To identify the cell types involved in vascular remodeling that
are present within the neointima, serial sections of both ligated and
contralateral arteries were subjected to immunohistochemical
analysis employing markers of macrophages (Mac-2/Gal3; soluble
lactose binding lectin-2) (Fig. 3a, b, c) and smooth muscle cells
(smooth muscle actin a-SMA) (Fig. 3d, e, f). These analyses
revealed that the majority of neointimal cells in LRP1+/+ carotid
arteries were macrophages (Fig. 3b) along with a relatively small
number of a-SMA positive cells (Fig. 3e). In contrast, in the
neointima of macLRP1-/- mice, there were a large number of a-
SMA positive cells (Fig. 3f) as well as macrophages (Fig. 3c). In
both LRP1+/+ and macLRP1-/- mice, the macrophages resemble
foam cell macrophages, most likely resulting from the ‘‘Western
diet’’, and these cells are known to contribute significantly to
vascular remodeling [15,18]. We characterized the total expres-
sion of LRP1 and Mac-2 antigen in the arterial wall of LRP1+/+
and macLRP1-/- mice using immunoblot analysis, and the results
revealed that the expression of LRP1 in vessels undergoing ligation
were substantially increased (Fig. 3g), likely due to the increased
accumulation of smooth muscle cells in the lesions. There was no
significant difference in LRP1 levels when LRP1+/+ vessels were
compared with vessels from macLRP1-/-, likely reflecting the
abundance of LRP1 in fibroblasts and vascular smooth muscle
cells, and the fact that the lesion only occurs in a portion of the
entire vessel. Mac-2 immunoblot analysis confirmed the increase
in macrophage recruitment into the lesions in both LRP1+/+ and
macLRP1-/- mice (Fig. 3h).
Figure 1. Effective deletion of the Lrp1 gene in macrophages from macLRP1-/- mice. a) Bone marrow derived macrophages from LRP1+/+
and macLRP1-/- mice were analyzed for LRP1 expression by immunoblot analysis. b) Resident macrophages were isolated by peritoneal lavage and
incubated with fluorescent labeled RAP for 1 h at 37
oC. RAP-positive, F4/80 positive cells were then determined by FACS analysis.
doi:10.1371/journal.pone.0028846.g001
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carotid arteries reveal enhanced gene expression of TGF-
b2 in macLRP1-/- mice
To assess the influence of macrophage LRP1 on events
occurring in the vessel wall during vascular remodeling induced
by ligation and high fat diet, we employed quantitative RT-PCR
arrays to identify changes in mRNA levels of genes involved in this
process. As a control for these experiments, we isolated vessels
from LRP1+/+ and macLRP1-/- mice that had not undergone
ligation. The changes in gene expression were analyzed by a 2-way
ANOVA analysis to evaluate the effect of treatment (control vs.
ligation) as well as the effect of genotype (WT vs. macLRP1-/-) on
the outcome. At day 14 following surgery, the ligated vessels of
both LRP1+/+ and macLRP1-/- mice reveal changes in multiple
genes encoding extracellular matrix components, pro-inflamma-
tory cytokines and cell cycle related genes whose mRNA levels
were altered in response to treatment (Table 1). Importantly, only
three genes of 84 tested were identified whose mRNA levels varied
as a result of genotype differences (i.e. as a consequence of deletion
of LRP1 in macrophages), and these are shown in Figure 4.
One of these genes is the profibrotic gene TGF--b2, a member
of the TGF-b family. There are three TGF-b family members,
TGF-b1, TGF-b2, and TGF-b3, all of which are expressed in the
vessel wall and have overlapping functions [19]. Smith et al. [13]
demonstrated a prominent role for transforming growth factor–
b(TGF-b) in vascular remodeling. During wound healing and
tissue repair, TGF-b is known to induce myofibroblastic trans-
differentiation [20], SMC proliferation [21,22] and promote
matrix deposition [23]. These events occur via signaling pathways
involving the downstream effectors Smad2 and Smad3. A second
gene whose expression is enhanced in the macLRP1-/- mice is
Pdgfa, a growth factor that is known to contribute to vascular
remodeling by promoting the proliferation and migration of
vascular smooth muscle cells. Expression of the Pdgfa gene is
induced by low levels of TGF-b [21,22]. Increased expression of
the Eln gene may also be a consequence of increased TGF-b2
expression, as activation of the TGF-b signaling pathway induces
expression of the Eln gene [24]. Interestingly, qRT-PCR analysis
of the contralateral vessel reveals no difference in TGF-b2 mRNA
levels in LRP1+/+ and macLRP1-/- mice.
To confirm that TGF-b2 is expressed during vascular
remodeling, immunohistochemical analysis was performed on
sections of the carotid artery from LRP1+/+ and macLRP1-/-
mice. The results, shown in Fig. 5, demonstrate that TGF-b2i s
expressed upon carotid ligation, with the majority of TGF-b2
located within the neointima. Further, there appears to be more
extensive staining of TGF-b2 in arteries from the macLRP1-/-
mice (Fig. 5c).
To determine if the TGF-b signaling pathway is activated
during vascular remodeling, we stained tissue sections with specific
antibodies against phosphorylated forms of Smad2/3 (pSmad2/3),
which represents activated mediators of transcriptional activation
of the TGF-b signaling pathway. pSmad2/3 expression (Fig. 5, d,
e, f) was particularly abundant in extensively remodeling areas
where neo-intimal thickening occurs. Quantification of the
pSmad2/3 positive cell nuclei in these remodeling areas revealed
more extensive activation of the TGF-b signaling pathway in
macLRP1-/- mice (Fig 5 g). Further, enhanced collagen deposi-
tion was noted in vessels from the macLRP1-/- mice using Fibrin-
Fraser-Lendrum stained sections (Fig 6).
Figure 2. LRP1 expressed in macrophages protects against vascular remodeling in the carotid-ligation model. a) Photomicrographs
showing the representative Elastic-Van Gieson staining of contralateral (left panels) and ligated vessels (right panels) in LRP1+/+ (top) and macLRP1-/-
(bottom) mice. b) H&E staining of the serial sections of the same artery as in (a). c) Morphometric measurements of the total vessel area, adventitia
area, media area and intima area were measured for LRP1+/+ (n=20) and macLRP1-/- (n=20) mice (*p=0.03; **p=0.009, Students t-test). d) Ratio of
the Intima over the Media is represented for LRP1+/+ and macLRP1-/- mice (***p=0.010, Students t-test).
doi:10.1371/journal.pone.0028846.g002
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in this receptor in both medial and neointimal cells (Fig. 7a, b, c) of
macLRP1-/- mice. The neointimal cells in both of the remodeled
LRP1+/+ and macLRP1-/- carotid arteries were in a proliferative
state as shown with proliferating cellular nuclear antigen (PCNA)
staining (Fig. 7d, e, f). TUNEL staining did not detect apoptotic
cells in the vessel wall (data not shown).
LRP1 attenuates TGF- b2 mRNA levels in macrophages
Macrophagesareknown toproduce TGF-b2,and todetermineif
the increase in TGF-b2 mRNA in macLRP1-/- mice could result
from alterations in gene expression of the macLRP1-/- macro-
phages, we examined the expression of this gene in bone marrow
derived macrophages (BMDM). Since our PCR array data revealed
a substantial increase in TNF-a mRNA in vessels undergoing
ligation (see Table I), we examined the effects of TNF-a on TGF-b2
expression in LRP1+/+ and LRP1-/- BMDM. The results revealed
that when BMDM were cultured in the presence of TNF-a, those
from macLRP1-/- mice express significantly more mRNA for TGF-
b2 than LRP1+/+ macrophages (Fig. 8a). The impact of LRP1
deletion in macrophages appears specific for the TGF-b2 gene, as
expression of genes known to be sensitive to TNF-a, such as the
SerpinB2 gene [25], remained unchanged when macLRP1-/-
macrophages were compared to those expressing LRP1 (Fig. 8b).
TGF-b2 induces ERK1/2 and SMAD activation in vascular
smooth muscle cells
While a large number of studies have investigated the effect of
TGF-b1 on vascular smooth muscle cells, at present very little is
known regarding the potential of TGF-b2 to affect vascular
smooth muscle cell function. We therefore investigated the effects
of TGF-b2 on the MAPK signaling pathway as well as the
canonical TGF-b pathway in vascular smooth muscle cells. The
MAPK pathway is of interest, as this pathway is known to play a
pivotal role in neointima formation during restenosis [26]. The
results, shown in Fig 9a, reveal that TGF-b2 activates both the
MAPK pathway as well as the TGF-b pathway as evidence by
phosphorylation of ERK1/2 and SMAD 2/3, respectively. We
also examined the ability of TGF-b2 to activate the ERK1/2 and
SMAD 2/3 pathway in macrophages, and found that TGF-b2
activates both pathways in macrophages, but not in an LRP1-
dependent manner (Fig 9b). Interestingly, while we observed a
robust ERK1/2 activation when TGF-b1 was incubated with
LRP1 deficient macrophages (fig 9c, right panel), induction of
ERK1/2 activation was attenuated in LRP1+/+ macrophages
(Fig. 9c, left panel), revealing that LRP1 suppresses TGF-b1
mediated ERK activation.
LRP1 binds TGF-b2 and regulates the levels of this
molecule
LRP1 has been suggested to participate as a TGF-b receptor,
and crosslinking studies in cells have revealed an association of
TGF-b1 with LRP1 [27]. However, it is not known if TGF-b2i s
able to bind to LRP1. Thus, to determine if LRP1 is able to
directly bind TGF-b2, we conducted surface plasmon resonance
experiments with purified components. The results reveal that
TGF-b2 binds directly to LRP1 in a dose-dependent manner
(Fig. 10a). Estimation of the affinity of LRP1 for TGF-b2 was
Figure 3. Immunohistochemical analysis of macrophage and a-SMC actin positive cells in the neointima. Cross-sections of contralateral
(a,d) and ligated (b,c,e,f) carotid arteries 2 weeks after ligation. Representative expression of Mac-2 (a,b,c) and a-SMA (d,e,f) antigen in contralateral
and ligated vessels. Internal elastic lamina (IEL) is marked by a black arrow. Arrowhead indicates the cells positive for antibody staining. L shows
lumen. g) Immunoblot analysis of LRP1 expression in contralateral and surgery vessels of LRP1+/+ (n=2) and macLRP1-/- (n=2) mice. Gels were
analyzed using NIH imageJ h) Immunoblot analysis of Mac-2 expression in contralateral and ligated vessels of LRP1+/+ (n=4) and macLRP1-/- (n=4)
mice. Gels were analyzed using NIH imageJ.
doi:10.1371/journal.pone.0028846.g003
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value of 222 nM. This value is comparable to the affinity
(KD=157 nM) measured for the binding of TGF-b1 to soluble
forms of the extracellular domain of the type II TGF-b receptor
[28]. To confirm the surface plasmon resonance experiments, we
performed co-immunoprecipitation experiments of cell extracts
following cross-linking of
125I-labeled TGF-b2 to cells. The results
of the experiment (Fig. 10c) reveal that
125I-labeled TGF-b2 co-
immunoprecipitated with LRP1. The specificity of the interaction
was confirmed by demonstrating that
125I-TGF-b2 was not
immunoprecipitated in LRP1-deficient macrophages. Interesting-
ly, RAP was unable to compete for binding suggesting that TGF-
b2 binds to a region of LRP1 that is distinct from the LDLa
repeats.
The ability of LRP1 to directly bind TGF-b2 suggests that
expression of LRP1 might reduce the levels of TGF-b2 due to
LRP1-mediated catabolism. To test this, we measured the TGF-
b2 antigen level in conditioned media collected from LRP1+/+
and macLRP1-/- macrophages by immunoblot analysis. These
studies revealed that the concentration of TGF-b2 in conditioned
Table 1. Genes whose expression levels change upon
atreatment.
bFold
bFold
Symbol Change
cp Symbol Change
cp
Abca1 2.2 0.0426 Lama1 22.5 0.06
Ace 6.2 0.0427 Msr1 33.2 0.0043
Apoa1 27.8 ,0.0001 Nfkb1 21.2 0.2865
Apob 7.3 0.003 Npy 22349.7 0.0019
Bax 5.5 0.0014 Nr1h3 22.1 0.0116
Bcl2a1a 12.0 0.0027 Pdgfa 2.0 0.0028
Bcl2l1 22.8 0.0001 Pdgfb 8.3 0.0219
Bid 1.3 0.0233 Pdgfrb 9.6 ,0.0001
Ccl2 4.1 0.0249 Ppara 231.7 0.0019
Ccl5 5.5 0.008 Ppard 3.3 0.0059
Ccr1 5.9 0.0654 Pparg 212.5 0.0062
Cd44 1.8 0.0051 Ptgs1 24.2 0.0012
Col3a1 3.2 0.0016 Sele 3.7 0.0099
Ctgf 2.2 0.0245 Sell 30.3 0.002
Cxcl1 8.9 0.0184 Selplg 14.8 0.0002
Eln 7.9 0.0023 Serpinb2 23.0 0.097
Fabp3 259.2 0.0009 Serpine1 15.3 0.0755
Fas 22.0 0.0009 Sod1 23.3 0.0005
Fn1 41.9 0.0002 Spp1 39.7 ,0.0001
Icam1 7.7 0.0004 Tgfb1 7.2 0.0399
Il1a 32.8 0.0025 Tgfb2 1.9 0.0024
Il1b 47.3 0.008 Thbs4 215.4 ,.0001
Il1r2 6.3 0.0041 Tnc 83.2 ,0.0001
Il3 244.9 0.0001 Tnf 6.3 0.0047
Il4 22.1 0.005 Tnfaip3 4.8 0.0053
Il5 21.9 0.0148 Vcam1 2.9 0.0056
Itga2 1.3 0.1831 Vegfa 24.1 0.0016
Itgax 143.7 ,0.0001 Vwf 3.7 0.0967
Itgb2 7.2 0.0006
aTreatment refers to carotid ligation surgery.
bWT control mice (i.e. no treatment) vs. WT mice undergoing treatment. The
fold change in macLRP1-/- mice with no treatment vs. treatment was very
similar, but is not shown.
c2 way ANOVA, p for control (no treatment) vs. treatment.
doi:10.1371/journal.pone.0028846.t001
Figure 4. qRT-PCR array analysis identifies increased expres-
sion of Tgf-b2, Pdgfa and Eln mRNA in macLRP1-/- vessels. Total
RNA was isolated from carotid arteries of control mice (no surgery) or
mice undergoing carotid ligation. Carotid arteries from 3–4 mice were
pooled to generate a single sample (n) for analysis. qRT-PCR array
analysis using the atherosclerosis array from SABiosciences
TM was
performed. Only 3 of the 84 genes were significantly dependent upon
genotype when ligated vessels were compared from LRP1+/+ mice with
those from macLRP1-/- mice as assessed by 2-way ANOVA analysis. The
relative levels of TGF-b2 (a), Pdgfa (b) and Eln (c) are shown for controls;
LRP1+/+ (n=3), macLRP1-/- (n=3) and for surgery; LRP1+/+ (n=3),
macLRP1-/- (n=3). Two way ANOVA revealed significant effects for
genotype (*p=0.009; **p=0.023; ***p=0.049) and treatment
(*p=0.002; **p=0.002; ***p=0.002) with no significant genotype X
treatment interaction.
doi:10.1371/journal.pone.0028846.g004
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LRP1 expressing cells (Fig. 10d). Since quantitative RT-PCR
revealed that the mRNA levels for TGF-b2 is identifical in resting
macrophages from LRP1+/+ and macLRP1-/- mice (data not
shown), together the results reveal that LRP1 is also capable of
regulating the levels of TGF-b2 protein, most likely by binding and
mediating the catabolism of this molecule.
Discussion
Restenosis is a process that results from accumulation of vascular
smooth muscle cells in the intima following vessel injury. It is
currently thought that injury induces vascular smooth muscle de-
differentiation from a ‘contractile’ phenotype to a ‘synthetic’
phenotype resulting in enhanced proliferation and migration of
the de-differentiated cells into the intima [29]. Further, these cells
synthesize significant amounts of extracellular matrix proteins.
Macrophagesaccumulate early inthelesions[14,15] and contribute
to vascularremodeling followinginjury. Inthe currentinvestigation,
we were interested in the contribution of macrophage LRP1 to this
process. Our results reveal that LRP1 expression in macrophages
minimizes the extent of vascular remodeling in the carotid ligation
model, and when LRP1 is genetically deleted in these cells, the
formation of the neointima is much more extensive.
To gain insight into the potential mechanisms by which
macrophage LRP1 might regulate vascular remodeling, quantita-
tive RT-PCR arrays were employed. These data revealed that
TGF-b2 mRNA levels in the vessel wall of macLRP1-/- mice were
more than 2-fold higher than LRP1+/+ mice. Immunohistochem-
ical analysis of pSMAD2/3 expression confirmed excessive
activation of the TGF-b signaling pathway in the vessels of
macLRP1-/- mice. Several experiments confirmed that LRP1
expression in macrophages plays a major role in regulating levels
of TGF-b2. First, we demonstrated that treatment of bone marrow
derived macrophages with TNF-a leads to a 2-fold increase in the
levels of TGF-b2 mRNA in LRP1-deficient cells. Second, we
found by employing surface plasmon resonance experiments as
well as crosslinking experiments followed by co-immunoprecipita-
Figure 5. Increased activation of the TGF-b signaling pathway
during vessel remodeling in macLRP1-/- mice. Representative
images from contralateral (a,d) and ligated vessels (b,c,e,f) stained for
TGF-b2 (a,b,c) or phospho-Smad 2/3 (d,e,f). Internal elastic lamina (IEL) is
marked by a black arrow. Arrowheads indicate a cell positive for
antibody staining while L marks the lumen. (g) five fields from each
mouse were assessed for the number of phospho-Smad2/3 positive
nuclei for LRP1+/+ (n=2 mice) and macLRP1-/- (n=2 mice). *p,0.0001,
students t-test.
doi:10.1371/journal.pone.0028846.g005
Figure 6. Evaluation of matrix deposition in neointima.
Photomicrographs showing the representative Fibrin-Fraser-Lendrum
stained sections of contralateral (a) and ligated vessels (b,c). Internal
elastic lamina (IEL) is marked by black arrow. White asterisk show
collagen matrix specific green color deposition. L identifies the lumen.
doi:10.1371/journal.pone.0028846.g006
Figure 7. Increased cell proliferation and PDGFR-bexpression
during vascular remodeling. Representative anti-PDGFR-b staining
(a,b,c) and anti-PCNA staining (d,e,f) for proliferating cells of contralat-
eral (a,d) and ligated carotid arteries (b,c,e,f). Internal elastic lamina (IEL)
is marked by a black arrow. Arrowheads indicate the cells positive for
antibody staining. L identifies the lumen.
doi:10.1371/journal.pone.0028846.g007
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macrophages deficient in LRP1 accumulate twice as much TGF-
b2 protein in conditioned media when compared with LRP1
expressing macrophages despite the fact that TGF-b2 mRNA is
unchanged. Thus it appears that LRP1 regulates TGF-b2 levels by
binding this molecule and mediating its catabolism. Based on these
data, we propose that the molecular mechanism by which
macrophage LRP1 suppresses vascular remodeling is via modu-
lating TGF-b2 expression and by attenuating TGF-b signaling.
Upon deletion of LRP1 in macrophages, increased TGF-b2
expression results in increased Pdgfa gene expression, which we
propose leads to enhanced activation of the PDGF signaling
pathway. Increases in Pdgfa gene expression in turn may account
for increased smooth muscle cell migration and proliferation in the
macLRP1-/- mice. It is interesting to note that IL3 levels are
extensively increased in both WT and LRP1-deficient mice upon
vascular remodeling. IL3 is known to stimulate migration and
proliferation of vascular smooth muscle cells [30], and likely
contributes to the vascular remodeling in this model.
Several studies support the notion that LRP1 is an important
modulator of the TGF-b signaling pathway. Thus, Huang et al.
[27] demonstrated that
125I-labeled TGF-b could be crosslinked to
LRP1, and that this interaction was inhibited by the LRP1
antagonist, receptor associated protein, RAP. These studies also
demonstrated that murine fibroblasts in which LRP1 was
genetically deleted were not sensitive to growth inhibition by
TGF-b [27]. Further, mice with a genetic deletion of LRP1 in
vascular smooth muscle cells on an LDLr-deficient background
demonstrated nuclear accumulation of phosphorylated Smad2/3
in the aorta [31], revealing that in an atherosclerosis model,
smooth muscle cell LRP1 suppresses the TGF-b signaling
pathway. The effects of TGF-b on the cells of the vasculature
Figure 8. TNF-a attenuates Tgf-b2 expression in LRP1 expressing macrophages. a) Bone marrow derived macrophages were treated with
TNF-a overnight. Total mRNA from each sample was isolated and analyzed by qRT-PCR array analysis using the atherosclerosis array from
SABiosciences
TM. ThelevelsofTgf-b2 (a)andSerpinB2(b)areshownforLRP1+/+ andmacLRP1-/-cells(n=3foreachcelltype;*p=0.007,Studentst-test).
doi:10.1371/journal.pone.0028846.g008
Figure 9. TGF-b2 induces SMAD and MAPK signaling in hAoSMCs and TGF-b-mediated ERK activation is inhibited in LRP1+/+
expressing macrophages. a) hAoSMCs were serum starved for overnight and induced with 2 ng/ml TGF-b2 at indicated times. Cell extracts were
analyzed for phospho-SMAD2 (S465/467), phospho-Erk1/2 (T202/Y204) or a/b tubulin for loading control. Results are representative of two
independent experiments. b,c) Bone marrow derived macrophages from LRP1+/+ or macLRP1-/- mice were treated with TGF-b2 (b) or TGF-b1 (c). Cell
extracts were then analyzed for phospho-Erk1/2 and/or phospho-SMAD2 by immunoblot analysis. a/b tubulin levels represents loading control
measured by immunoblot analysis.
doi:10.1371/journal.pone.0028846.g009
Macrophage LRP1 Protects during Restenosis
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28846are complex. For example, TGF-b can both inhibit [32] as well as
stimulate [21,33] the growth of vascular smooth muscle cells
depending on the conditions. Based on its ability to inhibit
vascular smooth muscle cell growth and on its anti-inflammatory
activity, it has been suggested that TGF-b plays a protective role in
the development of atherosclerosis [34]. However, substantial
evidence reveals an important contribution of the TGF-b signaling
pathway in restenosis. First, gene transfer of TGF-b into the wall
of normal porcine vessels resulted in significant deposition of
extracellular matrix accompanied by intimal and medial hyper-
plasia [35]. Second, transfection of ribozyme oligonucleotides
targeted to a common sequence of TGF-b during balloon injury of
rat vessels resulted in diminished TGF-b expression and a
significant reduction in collagen synthesis and in neointima
formation [36]. Third, injection of a recombinant soluble TGF-
b receptor II into a rat following balloon injury resulted in a
reduction in intimal lesion formation [13]. Taken together, these
studies provide compelling evidence that TGF-b participates in
vascular remodeling during restenosis. The findings in the current
study demonstrate that macrophage LRP1 regulates TGF-b2
levels and attenuates the TGF-b signaling pathway, identifying a
new paradigm for regulating vascular remodeling.
In addition to its potential to regulate the TGF-b signaling
pathway, LRP1 also modulates other signaling pathways. For
example, LRP1 associates with the PDGFR-b [37,38] and
modulates the MAPK and Akt/phosphatidylinositol 3-kinase
pathways [39] and PDGF-stimulated vascular smooth muscle cell
proliferation in vivo [7]. In Schwann cells following peripheral
nerve injury, LRP1 functions as a pro-survival receptor, and
silencing of Schwann cell LRP1 with siRNA decreases phosphor-
ylated Akt and increases activated caspase-3 [40]. Recent findings
reported that LRP1 in thioglycollate-elicited peritoneal macro-
phages suppressed their inflammatory response to LPS treatment
[41]. This was found to occur by a mechanism involving
proteolysis of the LRP1 ectodomain, following by subsequent c-
secretase-dependent release of the LRP1 intracellular domain
(ICD). The LRP1-ICD was observed to interact with interferon
regulatory factor 3 resulting in enhanced nuclear export and
degradation. All of these studies, together with the results of the
current investigation, highlight the potential of LRP1 to modulate
inflammatory events, with the outcome highly dependent upon the
initiating stimulus and cellular context.
Within macrophages, LRP1 has been shown to reduce the
extent of atherosclerosis in LDL receptor/apoE double knockout
Figure 10. LRP1 binds TGF-b and regulates its levels. a) Surface Plasmon resonance confirms binding of TGF-b2 to LRP1 immobilized on SPR
chip. The red line shows the best fit to a pseudo-first order process also containing a non-specific binding component. b) Rmax determined from the
fits in (a) are replotted vs TGF-b2 concentrations. The line shows the best fit to a binding isotherm using non-linear regression analysis, revealing a KD
of 222 nM. c) TGF-b2 co-immunoprecipitates with LRP1 in LRP1+/+ macrophages. Macrophages from LRP1+/+ or macLRP1-/- mice were incubated
with
125I- TGF-b2 plus or minus RAP. Following crosslinking, cell extracts were subjected to immunoprecipitation and the immunoprecipitated
proteins separated by SDS-PAGE and transferred to nitrocellulose membrane. The membranes were then exposed to autoradiographic film. d) TGF-b2
accumulation in macrophage condition media analyzed by immunoblot analysis. Bone marrow derived macrophages were grown in serum-free
media for 72 h. Concentrated culture media (0.5 ml) were subjected to western blot analysis for TGF-b2 expression. Gels were analyzed using NIH
ImageJ, and integrated bands were normalized to total cell protein (n=3 for each cell type, *p=0.0168, Students t-test).
doi:10.1371/journal.pone.0028846.g010
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mechanisms by which this occurs is not understood at this time,
but prior work has shown that macrophage migration depends
upon LRP1 in coordination with the integrin Mac-1, tissue-type
plasminogen activator and its serpin inhibitor, PAI-1 [42], and
thus some of the effects may be attributed to increased
macrophage retention within the lesion. The results of our current
studies further reveal that regulation of the TGF-b signaling
pathway may contribute to this effect. However, we need to keep
in mind that LRP1 is known to bind over 30 distinct ligands, and
thus may protect the vessel wall by a variety of mechanisms,
including modulation of signaling pathways as well as via
catabolism of various molecules.
In summary, we have demonstrated a protective effect of LRP1
expressed in macrophages on the vessel wall which plays a vital
role in reducing neointimal formation thereby preserving vascular
function upon vessel wall injury. One of the mechanisms by which
this occurs appears to involve regulation of the TGF-b signaling
pathway. Future studies with these genetically modified mice will
be important for identifying additional mechanisms by which
LRP1 protects the vessel wall by preserving lumen diameter and
function during restenosis.
Materials and Methods
Ethics statement
All animal work in this manuscript was conducted in
accordance with the Animal Welfare Act, Public Health Service
(PHS) Policy on Humane Care and Use of Laboratory Animals,
and the Guide for the Care and Use of Laboratory Animals. All
work was reviewed and approved by the University of Maryland
Institutional Animal Care and Use Committee. The Animal
Welfare Assurance number is: A3200-01, and the protocol
number approved is: #0310019, approval date: 3/18/2011.
Animal Model
LDLr
-/- mice were crossbred with mice expressing floxed loxP
sites flanking the LRP1 gene (both kindly provided by J. Herz,
Dallas) as described [43] to generate LDLR
-/-,LRP1
flox/flox mice.
Then LDLR
-/-,LRP1
flox/flox mice were crossed with mice expressing
Cre recombinase, under control of myeloid lineage-specific
lysozyme M promoter [44] allowing deletion of the targeted gene
in mature macrophages and granulocytes (LysMCre, kindly
provided by I. Fo ¨rster, Munich). Since LRP1 is only expressed
in monocytes/macrophages and not granulocytes, this cross
generated either macrophage specific LRP1 deletion
(macLRP1-/-) or LRP1 wild type mice (LRP1+/+). Mice were
weaned at 3 weeks, maintained on a 12-hour light/12-hour dark
cycle and fed standard rodent chow (4% wt/wt fat, Harlan Teklad)
and water ad libitum. Littermate siblings of Cre- (LRP1+/+;
LDLR
-/-, LRP1
flox/flox, Cre
-/-) or Cre+ (macLRP1-/-; LDLR
-/-
LRP1
flox/flox, Cre
-/+) were used in all experiments. Blood flow
cessation model for vessel wall remodeling surgery was performed
as described [14]. Following surgery, mice were placed on a
‘‘Western’’ diet (21% wt/wt fat, 0.2% wt/wt cholesterol (Harlan
Teklad TD-88137)) for two weeks.
Quantitative real-time reverse transcriptase (RT)-PCR
Total RNA from snap frozen carotid arteries or cultured
BMDMs were isolated using Trizol (Invitrogen) reagent as
directed by the manufacturer. The mRNA from 3–4 mice were
pooled for each n. In the case of bone marrow derived
macrophages, macrophages from 2–3 mice were pooled for total
RNA isolation. 1 mg total RNA was used to synthesize cDNA by
using the First Strand cDNA Synthesis Kit (SABiosciences). Real-
time PCR was performed on an ABI 7900 instrument (Applied
Biosystems) by using RT
2 Real-Time SYBR Green/ROX PCR
Master Mix (SABiosciences) and the transcription profile of the
Mouse Atherosclerosis RT
2 Profiler
TM PCR Arrays (SABios-
ciences). Data were analyzed based on DDCt fold-change method.
Hsp90ab1 and Actb were used as house-keeping genes for data
normalization.
Statistical Analysis
Data are presented as means 6 Std and were compared using a
2-way ANOVA test for comparisons of 4 groups and a Student t-
test for 2 group comparisons. Threshold for significance was set as
1.5 fold change and p#0.05. All values represent at least 3
independent trials.
Vessel Morphometry and Immunohistochemistry
Two weeks after inducing arterial injury, animals were
anesthetized and perfused with phosphate buffered saline. The
entire neck was dissected from each mouse and fixed in 10%
buffered formalin. The whole neck was decalcified before
embedding in paraffin. Identical whole-neck cross-sections of
5 mm were made from the distal side of the neck beginning at
the point of the distally ligated suture until aortic bifurcation. The
whole-neck sections were used to evaluate both the injured and
the uninjured control vessels on the same section. For each mouse,
the apex of lesion was determined by analyzing serial sections at
100-mm intervals for the entire section of the artery. At every
100 mm interval, parallel sections were subjected to routine
hematoxylin and eosin (H&E) staining as well as to elastic Van-
Gieson (EVG) staining of elastic lamina. In all cases, the apex of
the lesion occurred within the same approximate distance from the
ligation (0.5 mm). Morphometric measurements were done using
ImageJ software on blinded samples. Immunostaining for the
following primary antibodies were performed on serial sections at
the apex of the lesion: Mac-2 (Cedarlane, Canada), a-SMA (Clone
1A4, Sigma-Aldrich, St Louis, MO), TGF-b2 (Thermo Scientific,
Rockford, IL), phospho-Smad2/3 (pSmad2/3) (Ser 423/425)
(Santa Cruz Biotechnology, Santa Cruz, CA), PDGFRb (Chemi-
con Int.), proliferating cell nuclear antigen (PCNA, Clone PC10,
Dako, Carpinteria, CA). Quantification of pSMAD2/3 positive
cells was achieved by counting positive nuclei in five random
optical fields for two independent remodeling carotid arteries per
genotype.
Surface plasmon resonance
Purified LRP1 was immobilized onto a CM5 sensor chip surface
at 5.8 fmol/mm
2 (3,500 RU) density, by amine coupling in
accordance with the manufacturer’s instructions (BIAcore AB).
One flow cell was activated and blocked with 1 M ethanolamine
without any protein and was used as a control surface to normalize
SPR signal from receptors immobilized with flow cells. All of the
binding experiments were conducted in standard HBS-P buffer,
pH 7.4 (BIAcore AB), containing 0.005% Tween 20 and 1 mM
CaCl2 at a flow rate of 20 ml/min and temperature of 25uC.
Sensor chip surfaces were regenerated by 15s pulses of 100 mM
H3PO4. All injections used the Application Wizard in the
automated method. Data were analyzed by fitting to a pseudo-
first order process also measuring non-specific binding. The
maximum change in response units (Rmax) from this analysis was
replotted versus TGF-b2 (Sigma) concentrations (TGF-b2 con-
centrations were: 6, 12, 15, 50, 100 and 200 nM), and the data
were fit to a single class of sites by nonlinear regression analysis
using SigmaPlot 11 software.
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Bone marrow derived macrophages were generated as described
[17]. Briefly, primary monocytes were seeded at 2610
6/6m m
tissue culture dish and cultured in Bone Marrow Macrophage
Growth Medium (BMMGM; DMEM supplemented with 10%
FBS, L929 conditioned medium (14% of final volume), penicillin,
streptomycin for 7 days. Immunoblot analysis with monoclonal 5A6
antibody [2] confirmed effective deletion of the LRP1 gene. For
signalingexperimentscultureswere starvedinDMEMforovernight
and induced with 30 ng/ml TGF-b1 or 2 ng/ml TGF-b2 (Sigma)
for 15 min. For qRT-PCR experiments BMD macrophages were
starved for overnight and induced with 40 ng/ml recombinant
mouse TNF-a (eBioscience). To analyze the TGF-b2 expression
and secretion, macrophages were serum starved for 72 hours and
conditioned media were collected and centrifuged to clear any cell
debris. Protein content of 0.5 ml of conditioned media was
concentrated by Strataclean (Stratagen) and analyzed with Western
blottingwith TGF-b2antibody.Relative intensitiesofTGF-b2were
analyzed using ImageJ software.
Tissue Culture and Immunoblotting
Primary human aortic smooth muscle cells (hAoSMC) were
purchased from CloneticsH which were distributed by Lonza
(Walkersville, MD) and were cultured according to manufacturer’s
protocol. All experiments were done between passages number 5
and 8. 70% confluent cells were starved overnight and treated with
2 ng/ml TGF-b2 (Sigma) for indicated times. Cells were washed
twice with ice cold PBS and lysates were prepared as described (16).
Equal amounts of protein from each lysate were resolved under
reducing conditions on 4-20% Tris-Glycine SDS gels. Proteins were
transferred to nitrocellulose and membranes were blocked in 3%
milk. Membranes were incubated with phospho-SMAD2
(pSMAD2) (S465/467) and phospho-p44/42 MAPK (pERK1/2)
(T202/Y204) and ab-tubulin (Cell Signaling). Antibody binding to
the immunoblot was detected by incubation with an appropriate
IRDye (LI-COR Biosciences) conjugated secondary antibody.
Immunoreactive bands were detected using LI-COR’s Odyssey
Infrared Imaging System.
Iodinationation and co-immunoprecipitation of TGF-b2
5 mg of carier-free TGF-b2 (Sigma-Aldrich) was radiolabeled
with Na
125I (Perkin Elmer) and Chloramine T (Acros Organics) as
described [45]. BMD macrophage media were replaced with 1 ml
assay buffer (1 mg/ml BSA, 25 mM Hepes pH 8, 1 mM CaCl2 in
DMEM) containing 17 nM
125I- TGF-b2o r1 7n M
125I- TGF-b2
and 2 mM RAP and incubated for 2 hrs at 4uC. Cells were washed
twice with 2 ml HBS. 1 ml 2 mM 3,39-Dithiobis[sulfosuccinimi-
dylpropionate] (DTSSP) in HBS was added to the cells and
incubated with the cells for 30 min at room temperature. The
reaction was stopped by incubating cells with 25 mM TrisHCl
(pH 7.5) for 15 min at room temperature. Cells were washed twice
with HBS and solubulized in 300 ml RIPA buffer (150 mM NaCl,
10 mM sodium phosphate (pH 7.0), 1 % NP40) with protease
inhibitors (complete mini EDTA-free protease inhibitor cocktail,
Roche). LRP1 bound protein complexes were immunoprecipitat-
ed with 10 mg monoclonal 5A6 antibody and 20 ml Protein G-
Dynabead (Invitrogen) overnight at 4uC. Immunoprecipitates
were washed twice with RIPA buffer. Supernatants were replaced
with 2x non-reducing SDS sample buffer and boiled for 5 min.
Extracted protein complexes were separated on 4–12 % gradient
polyacrylamide Tris-glycine gel. Gel was transferred to nitrocel-
lulose membrane and exposed to autoradiographic film for 5 days.
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